EGFR and COVID-19: In summary, our study validates ErbBs as druggable targets for antiviral, antiinflammatory, and tissue-protective approaches and proposes approved drugs with anti-pan-ErbB activity as an attractive class of repurposing candidates for COVID-19 and VEEV that may provide readiness for future outbreaks of other emerging viruses.